Lakefront Biotherapeutics NV
LKFT · Nasdaq · USD · Market cap $2.3B
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price33.31 USD at the 20 Nov 2026 close
- Our value readOvervalued vs our fair value, as of 20 Nov 2026
- Our regime readAccumulation, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 10.62)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $20.91 to $44.63, base estimate $26.92 (screen dated 2026-11-20).
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 10.62, read 2026-11-15
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
Lakefront Biotherapeutics NV holds its Accumulation at $33.31. The statistical read favours the buyers, held for 135 days.
| Phase | Accumulation |
| Quantitative state | The statistical read favours the buyers, held for 135 days |
| Price at the screen | $33.31 |
| Valuation | 2.47 trailing · -22.08 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.01 |
Five Screens: LKFT's Results
FAIL. Interest-bearing securities
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 0.20% | Below 33% | Pass |
| Interest-bearing cash | 85.43% | Below 33% | Fail |
| Receivables | 2.86% | Below 49% | Pass |
| Revenue purity | 4.17% | Below 5% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Lakefront Biotherapeutics's business is fine, but its cash and interest-bearing securities are about 85% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when LKFT's ethical verdict changes
Today LKFT does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Overvalued to fair value, as of 20 Nov 2026: it trades above our $26.92 fair value estimate.
USD, 2026-11-20 screen. The price runs 23.7% over base.
Street: 3 covering, consensus Hold. Average target −19%.
| Forward P/E | -22.1x |
| Trailing P/E | 2.5xvery cheap relative to earnings |
| EPS, trailing | 13.94 |
| EPS, forward | -1.56 |
| Revenue growth | -81.5%revenue is shrinking |
| Profit margin | 60.2%highly profitable on every dollar of sales |
| Return on equity | 20.1%an exceptional return on shareholder capital |
| FCF yield | 6.10% |
| Debt to equity | 0.20minimal debt: a conservative balance sheet |
| Current ratio | 32.84comfortably covers its short-term bills |
| Beta | 0.01barely tracks the market's swings |
| Short interest, float | 0.03% |
| 52-week range | 25.68 - 36.24 |
| Market cap | $2.3B |
LKFT-specific watchpoints · The things to watch: its business and earnings are exposed to Belgium and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from markup to accumulation since the last review.
The framework has shifted from accumulation to markup since the last review.
The framework has shifted from distribution to accumulation since the last review. Ethical screening: FAIL (changed).
Ethical screening: PASS.
Written on its date, before the outcome; never pruned.
- Lakefront Biotherapeutics Reports Nine Months 2026 Financial Results and Provides Business Update Yahoo Finance · 10d ago
- Lakefront to Present at the 2026 Jefferies Global Healthcare Conference in London Yahoo Finance · 11d ago
- Is Lakefront Biotherapeutics (ENXTAM:LKFT) Cheap Given Its Earnings Today? Yahoo Finance · 11d ago
- Should You Buy Lakefront Biotherapeutics - Sponsored ADR (LKFT) After Golden Cross? Yahoo Finance · 15d ago
- Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting Yahoo Finance · 17d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $27.45 | +4.1% | · | $1,041 | +4.1% |
| 2 months | $28.40 | +0.6% | · | $1,006 | +0.6% |
| 3 months | $31.93 | -10.5% | · | $895 | -10.5% |
| 6 months | $32.57 | -12.3% | · | $877 | -12.3% |
| 1 year | $28.31 | +0.9% | · | $1,009 | +0.9% |
| 2 years | $26.41 | +8.2% | · | $1,082 | +8.2% |
| 3 years | $43.04 | -33.6% | · | $664 | -33.6% |
| 5 years | $79.34 | -64.0% | · | $360 | -64.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever LKFT does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.